Optimizing dendritic cell-based immunotherapy in multiple myeloma: Intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients

British Journal of Haematology

Volumn 150, Issue 5, 2010, Pages 554-564

  Yi, Qing ^a   Szmania, Susann ^b   Freeman, John ^b   Qian, Jianfei ^a   Rosen, Nancy A ^b   Viswamitra, Sanjaya ^c   Cottler Fox, Michele ^b   Barlogie, Bart ^b   Tricot, Guido ^d   Van Rhee, Frits ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b Myeloma Institute for Research and Therapy   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

dendritic cells; idiotype; intranodal; multiple myeloma; vaccination

Indexed keywords

CD40 LIGAND; DENDRITIC CELL VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN IDIOTYPE; INTERLEUKIN 4; KEYHOLE LIMPET HEMOCYANIN; RECOMBINANT INTERLEUKIN 2; CANCER VACCINE; HEMOCYANIN; IMMUNOLOGICAL ADJUVANT; KEYHOLE-LIMPET HEMOCYANIN;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG ERUPTION; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; SKIN ALLERGY; TREATMENT OUTCOME; TREATMENT RESPONSE; BIOSYNTHESIS; CELL PROLIFERATION; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PROCEDURES; TRANSPLANTATION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; B-LYMPHOCYTES; CANCER VACCINES; CD40 LIGAND; CELL PROLIFERATION; DENDRITIC CELLS; FEMALE; FOLLOW-UP STUDIES; HEMOCYANIN; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNITY, CELLULAR; IMMUNOGLOBULIN IDIOTYPES; INTERFERON-GAMMA; INTERLEUKIN-4; MALE; MIDDLE AGED; MULTIPLE MYELOMA; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 77955780508     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08286.x     Document Type: Article

References (50)

1. Anderson, K.C. (2007) Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Experimental Hematology, 35, 155 162.
2. Banchereau, J. Steinman, R.M. (1998) Dendritic cells and the control of immunity. Nature, 392, 245 252.
3. Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.J., Pulendran, B. Palucka, K. (2000) Immunobiology of dendritic cells. Annual Review of Immunology, 18, 767 811.
4. Banchereau, J., Schuler-Thurner, B., Palucka, A.K. Schuler, G. (2001) Dendritic cells as vectors for therapy. Cell, 106, 271 274.
5. Barlogie, B., Jagannath, S., Desikan, K.R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., Mehta, J., Anaissie, E., Dhodapkar, D., Naucke, S., Cromer, J., Sawyer, J., Epstein, J., Spoon, D., Ayers, D., Cheson, B. Crowley, J. (1999) Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood, 93, 55 65.
6. Bendandi, M., Gocke, C.D., Kobrin, C.B., Benko, F.A., Sternas, L.A., Pennington, R., Watson, T.M., Reynolds, C.W., Gause, B.L., Duffey, P.L., Jaffe, E.S., Creekmore, S.P., Longo, D.L. Kwak, L.W. (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Medicine, 5, 1171 1177.
7. Bergenbrant, S., Yi, Q., Osterborg, A., Bjorkholm, M., Osby, E., Mellstedt, H., Lefvert, A.K. Holm, G. (1996) Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. British Journal of Haematology, 92, 840 846.
8. Blade, J., Dimopoulos, M., Rosinol, L., Rajkumar, S.V. Kyle, R.A. (2010) Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. Journal of Clinical Oncology, 28, 690 697.
9. Bogen, B. (1996) Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. European Journal of Immunology, 26, 2671 2679.
10. Bogen, B., Schenck, K., Munthe, L.A. Dembic, Z. (2000) Deletion of idiotype (Id)-specific T cells in multiple myeloma. Acta Oncologica, 39, 783 788.
11. Celluzzi, C.M., Mayordomo, J.I., Storkus, W.J., Lotze, M.T. Falo, L.D., Jr. (1996) Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. Journal of Experimental Medicine, 183, 283 287.
12. Diehl, L., den Boer, A.T., Schoenberger, S.P., van der Voort, E.I., Schumacher, T.N., Melief, C.J., Offringa, R. Toes, R.E. (1999) CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nature Medicine, 5, 774 779.
13. Dimopoulos, M.A., Moulopoulos, A., Smith, T., Delasalle, K.B. Alexanian, R. (1993) Risk of disease progression in asymptomatic multiple myeloma. American Journal of Medicine, 94, 57 61.
14. Eubel, J. Enk, A.H. (2009) Dendritic cell vaccination as a treatment modality for melanoma. Expert Review of Anticancer Therapy, 9, 1631 1642.
15. Facon, T., Menard, J.F., Michaux, J.L., Euller-Ziegler, L., Bernard, J.F., Grosbois, B., Daragon, A., Azais, I., Courouble, Y., Kaplan, G., Laporte, J.P., Degramont, A., Duclos, B., Leonard, A., Mineur, P., Delannoy, A., Jouet, J.P., Bauters, F. Monconduit, M. (1995) Prognostic factors in low tumour mass asymptomatic multiple myeloma: a report on 91 patients. The Groupe d'Etudes et de Recherche sur le Myelome (GERM). American Journal of Hematology, 48, 71 75.
16. Frassanito, M.A., Silvestris, F., Cafforio, P. Dammacco, F. (1998) CD8+/CD57 cells and apoptosis suppress T-cell functions in multiple myeloma. British Journal of Haematology, 100, 469 477.
17. French, R.R., Chan, H.T., Tutt, A.L. Glennie, M.J. (1999) CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nature Medicine, 5, 548 553.
18. Hsu, F.J., Benike, C., Fagnoni, F., Liles, T.M., Czerwinski, D., Taidi, B., Engleman, E.G. Levy, R. (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Medicine, 2, 52 58.
19. Hsu, F.J., Caspar, C.B., Czerwinski, D., Kwak, L.W., Liles, T.M., Syrengelas, A., Taidi-Laskowski, B. Levy, R. (1997) Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood, 89, 3129 3135.
20. Kugler, A., Stuhler, G., Walden, P., Zoller, G., Zobywalski, A., Brossart, P., Trefzer, U., Ullrich, S., Muller, C.A., Becker, V., Gross, A.J., Hemmerlein, B., Kanz, L., Muller, G.A. Ringert, R.H. (2000) Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nature Medicine, 6, 332 336.
21. Kwak, L.W., Campbell, M.J., Czerwinski, D.K., Hart, S., Miller, R.A. Levy, R. (1992) Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. New England Journal of Medicine, 327, 1209 1215.
22. Kyle, R.A. Greipp, P.R. (1980) Smoldering multiple myeloma. New England Journal of Medicine, 302, 1347 1349.
23. Li, Y., Bendandi, M., Deng, Y., Dunbar, C., Munshi, N., Jagannath, S., Kwak, L.W. Lyerly, H.K. (2000) Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood, 96, 2828 2833.
24. Lim, S.H. Bailey-Wood, R. (1999) Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. International Journal of Cancer, 83, 215 222.
25. Liso, A., Stockerl-Goldstein, K.E., Auffermann-Gretzinger, S., Benike, C.J., Reichardt, V., van Beckhoven, A., Rajapaksa, R., Engleman, E.G., Blume, K.G. Levy, R. (2000) Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biology of Blood and Marrow Transplantation, 6, 621 627.
26. Massaia, M., Borrione, P., Battaglio, S., Mariani, S., Beggiato, E., Napoli, P., Voena, C., Bianchi, A., Coscia, M., Besostri, B., Peola, S., Stiefel, T., Even, J., Novero, D., Boccadoro, M. Pileri, A. (1999) Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood, 94, 673 683.
27. Mayordomo, J.I., Zorina, T., Storkus, W.J., Zitvogel, L., Celluzzi, C., Falo, L.D., Melief, C.J., Ildstad, S.T., Kast, W.M., Deleo, A.B. Lotze, M.T. (1995) Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Medicine, 1, 1297 1302.
28. McKarney, I. (2007) Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer. Issues in Emerging Health Technologies, 101, 1 4.
29. Mosmann, T.R. Sad, S. (1996) The expanding universe of T-cell subsets: Th1, Th2 and more. Immunology Today, 17, 138 146.
30. Neelapu, S.S., Kwak, L.W., Kobrin, C.B., Reynolds, C.W., Janik, J.E., Dunleavy, K., White, T., Harvey, L., Pennington, R., Stetler-Stevenson, M., Jaffe, E.S., Steinberg, S.M., Gress, R., Hakim, F. Wilson, W.H. (2005) Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nature Medicine, 11, 986 991.
31. Nestle, F.O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G. Schadendorf, D. (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Medicine, 4, 328 332.
32. Osterborg, A., Yi, Q., Henriksson, L., Fagerberg, J., Bergenbrant, S., Jeddi-Tehrani, M., Ruden, U., Lefvert, A.K., Holm, G. Mellstedt, H. (1998) Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood, 91, 2459 2466.
33. Peest, D., Leo, R., Bloche, S., Hein, R., Stannat-Kiessling, S., Tschechne, B., Fett, W., Harms, P., Hoffmann, L., Bartl, R. et al (1995) Low-dose recombinant interleukin-2 therapy in advanced multiple myeloma. British Journal Haematology, 89, 328 337.
34. Qian, J., Wang, S., Yang, J., Xie, J., Lin, P., Freeman, M.E., III. Yi, Q. (2005) Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96. Clinical Cancer Research, 11, 8808 8815.
35. Reichardt, V.L., Okada, C.Y., Liso, A., Benike, C.J., Stockerl-Goldstein, K.E., Engleman, E.G., Blume, K.G. Levy, R. (1999) Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood, 93, 2411 2419.
36. Ridge, J.P., Di Rosa, F. Matzinger, P. (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature, 393, 474 478.
37. Shimizu, K., Fields, R.C., Giedlin, M. Mule, J.J. (1999) Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proceedings of the National Academy of Sciences of the United States of America, 96, 2268 2273.
38. Shimizu, K., Thomas, E.K., Giedlin, M. Mule, J.J. (2001) Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Research, 61, 2618 2624.
39. Szmania, S., Yi, Q., Cottler-Fox, M., Rosen, N.A., Freeman, J., Kordsmeier, B.J., Moreno, A., Shi, J., Barlogie, B., Tricot, G. van Rhee, F. (2005) Clinical-grade myeloma Ag pre-loaded DC vaccines retain potency after cryopreservation. Cytotherapy, 7, 374 384.
40. Titzer, S., Christensen, O., Manzke, O., Tesch, H., Wolf, J., Emmerich, B., Carsten, C., Diehl, V. Bohlen, H. (2000) Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. British Journal of Haematology, 108, 805 816.
41. Van den Hove, L.E., Meeus, P., Derom, A., Demuynck, H., Verhoef, G.E., Vandenberghe, P. Boogaerts, M.A. (1998) Lymphocyte profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: flow-cytometric characterization and analysis in a two-dimensional correlation biplot. Annals of Hematology, 76, 249 256.
42. Wen, Y.J., Barlogie, B. Yi, Q. (2001) Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood, 97, 1750 1755.
43. Wisloff, F., Andersen, P., Andersson, T.R., Brandt, E., Eika, C., Fjaestad, K., Gronvold, T., Holm, B., Lovasen, K. Tjonnfjord, G.E. (1991) Incidence and follow-up of asymptomatic multiple myeloma. The myeloma project of health region I in Norway. II. European Journal of Haematology, 47, 338 341.
44. Yi, Q. (2003a) Dendritic cell-based immunotherapy in multiple myeloma. Leukaemia & Lymphoma, 44, 2031 2038.
45. Yi, Q. (2003b) Immunotherapy in multiple myeloma: current strategies and future prospects. Expert Review of Vaccines, 2, 391 398.
46. Yi, Q., Bergenbrant, S., Osterborg, A., Osby, E., Ostman, R., Bjorkholm, M., Holm, G. Lefvert, A.K. (1993) T-cell stimulation induced by idiotypes on monoclonal immunoglobulins in patients with monoclonal gammopathies. Scandinavian Journal of Immunology, 38, 529 534.
47. Yi, Q., Osterborg, A., Bergenbrant, S., Mellstedt, H., Holm, G. Lefvert, A.K. (1995) Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood, 86, 3043 3049.
48. Yi, Q., Desikan, R., Barlogie, B. Munshi, N. (2002) Optimizing dendritic cell-based immunotherapy in multiple myeloma. British Journal of Haematology, 117, 297 305.
49. Young, J.W. Inaba, K. (1996) Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. Journal of Experimental Medicine, 183, 7 11.
50. Zitvogel, L., Mayordomo, J.I., Tjandrawan, T., DeLeo, A.B., Clarke, M.R., Lotze, M.T. Storkus, W.J. (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. Journal of Experimental Medicine, 183, 87 97.